Oncolytics Biotech (NASDAQ: ONCY)
Oncolytics Biotech Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Oncolytics Biotech Company Info
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.
News & Analysis
This High-Risk, High-Reward Biotech Is Worth a Look
The cards are certainly stacked against this biotech stock. But if its experimental lead drug proves effective, the sky could be the limit.
A New Cancer-Killing Virus
Oncolytics announces successful tests for cancer drug Reolysin.
Can Financial Innovation Unlock a Cure for Cancer?
Andrew W. Lo from the MIT Sloan School of Management has a rather Foolish idea for solving the world's biggest problems.
These 3 Stocks Aren't as Wobbly as They Appear
These stocks just rolled over. Can they come back?
This Week in Biotech
A look back at the biggest stories this week in biotech and what they mean for investors.
3 Humongous Health-Care Stocks This Week
Some of the sector's big movers.
Oncolytics Presents Promising Phase 1 Data in Colorectal Cancer
Reolysin has already advanced into a phase 2 trial in colorectal cancer.
Could a Virus Make You Lots of Money?
Can investors reap rewards from Oncolytics Biotech's cancer-killing virus?
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.